FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC - Concepedia

Concepedia

Publication | Open Access

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

DOI Full Paper Access

169

Citations

19

References

2018

Year

David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson,

Journal of Thoracic Oncology

Biomarker (Medicine)Therapeutic Drug MonitoringBiomarker AnalysisMedicinePd-l1–selected PatientsMetronomic TherapyPharmacologyClinical TrialsPharmacotherapyOncology

References

	Year	Citations

Page 1

Page 1